# EDGAR Filing Document

**Accession Number:** 0000921114
**File Stem:** 0001104659-26-048997
**Filing Date:** 2026-4
**Character Count:** 15054
**Document Hash:** b0df15f9e0982a55bdb3011801bcc55b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-048997.hdr.sgml**: 20260427

**ACCESSION NUMBER**: 0001104659-26-048997

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260424

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260427

**DATE AS OF CHANGE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armata Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000921114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911549568
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37544
- **FILM NUMBER:** 26896485

**BUSINESS ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066
- **BUSINESS PHONE:** 310-665-2928

**MAIL ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AmpliPhi Biosciences Corp
- **DATE OF NAME CHANGE:** 20130222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGETED GENETICS CORP /WA/
- **DATE OF NAME CHANGE:** 19940331

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 24, 2026**

**ARMATA PHARMACEUTICALS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Washington** | **001-37544** | **91-1549568** |
| (State or other jurisdiction <br> of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**5005 McConnell Avenue**<br> **Los Angeles, California** | &nbsp;&nbsp; **90066** |
| &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Zip Code) |

---

**(310) 655-2928**

(Registrant's Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| **Common Stock** | **ARMP** | **NYSE American** |

---

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On April 27, 2026, Armata Pharmaceuticals, Inc. (the "Company") announced that the Board of Directors

(the "Board") appointed Dr. Daniel Gilmer, 39, as a member of the Board, effective as of April 24, 2026, to serve until the Company's next annual meeting of the Company's shareholders.

The committee assignments of Dr. Gilmer have not been determined as of the time of this filing.

Dr. Gilmer will participate in the Company's standard non-management director compensation arrangement. The Company pays non-management directors a retainer of $40,000 per year, payable in cash. Dr. Gilmer will also be eligible to receive equity awards in amounts to be determined by the Board pursuant to the Company's 2016 Stock Incentive Plan, as amended (the "Plan"). A copy of the Plan was previously filed with the SEC as Exhibit 99.1 to the Company's Registration Statement on Form S-8 filed on June 10, 2019. In connection with his appointment, Dr. Gilmer is expected to receive an option award to purchase 51,280 shares of the Company's common stock, at an exercise price equal to the fair market value of one share of the Company's common stock on the date of grant, vesting in equal installments over a three-year period. The awards will be governed by the form of Stock Option Grant Notice and Option Agreement previously filed with the SEC on the Company's Quarterly Report on Form 10-Q filed on August 14, 2019. The Company also entered into an indemnity agreement with Dr. Gilmer, a form of which was previously filed with the SEC as Exhibit 99.2 to the Company's Current Report on Form 8-K, filed on January 19, 2016.

There are no arrangements or understandings between Dr. Gilmer and any other persons pursuant to which he was selected as a member of the Board. There are also no family relationships between Dr. Gilmer and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required

to be disclosed pursuant to Item 404(a) of Regulation S-K.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On April 27, 2026, the Company issued a press release announcing the appointment of Dr. Gilmer. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

**(d)Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [99.1](tm2612716d1_ex99-1.htm) | [Press Release, dated April 27, 2026.](tm2612716d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: April 27, 2026 | **Armata Pharmaceuticals, Inc.** | **Armata Pharmaceuticals, Inc.** |
|  | By: | /s/ David House |
|  | Name: | David House |
|  | Title: | Senior Vice President, Finance and Principal Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2612716d1_ex99-1img001.jpg)

**Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive**

**Daniel B. Gilmer, Ph.D. to its Board of Directors**

LOS ANGELES, Calif., April 27, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D. has joined the Company's Board of Directors, effective April 24, 2026. Dr. Gilmer has served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer Inc. ("Pfizer") since February 2025.

"I am pleased to welcome Daniel to our Board and look forward to leveraging his many years of experience spanning scientific discovery, commercial strategy, and patient access," stated Robin C. Kramer, Chair of Armata's Board of Directors. "Daniel has discovered and helped advance first-in-class anti-infective candidates and has played pivotal roles in the launch and commercialization of breakthrough therapies and diagnostics, including leading the U.S. launch of PAXLOVID<sup>TM</sup>. His perspectives on antimicrobial resistance, diagnostics, and access to innovation will be invaluable as we continue to advance our phage-based pipeline to commercialization."

"I am very excited to join Armata's Board and work alongside my fellow Directors and the leadership team to help the Company achieve its clinical and commercial goals," stated Dr. Gilmer. "Armata is developing precisely targeted bacteriophage therapeutics that have the potential to address the growing global crisis of antibiotic resistance. I look forward to contributing my experience in launching innovative anti-infectives and access-oriented initiatives to support this mission."

**Daniel B. Gilmer, Ph.D.** is an accomplished healthcare executive. At Pfizer, he leads an organization responsible for quality and promotional review across 50+ U.S. brands. His team works closely with medical, legal, and regulatory subject matter experts to advise commercial stakeholders on content quality, compliance, and risk-benefit balance. Previously, from April 2022 to February 2025, Dr. Gilmer led cross-functional teams in Pfizer's Antiviral and Diagnostics Business, where he launched PAXLOVID<sup>TM</sup> in the United States as it received New Drug Approval from the U.S. Food and Drug Administration (the "FDA"). Earlier at Pfizer, from April 2021 to April 2022, Dr. Gilmer worked in Inflammation & Immunology Commercial Development, where he helped shape strategy for a portfolio of rheumatology and immunology assets. Dr. Gilmer joined Pfizer in Research & Development in May 2019, where he contributed to Pfizer's COVID-19 vaccine-enabling operating model and R&D portfolio strategy.

Dr. Gilmer is an equal co-inventor on the patent for Exebacase (also termed "CF-301" or "PlySs2"), a first-in-class *Streptococcus* bacteriophage lysin. Exebacase received Fast Track and Breakthrough Therapy designations from the FDA before advancing to Phase 3 clinical trials. Dr. Gilmer has authored multiple peer-reviewed publications on phage lysins and antimicrobial resistance. Prior to joining Pfizer, Dr. Gilmer worked at McKinsey & Co. focusing on commercial growth strategies, market access, and lean manufacturing in the United States, Canada, and France. Earlier in his career, he conducted microbiology and infectious disease research at leading academic institutions and the National Institutes of Health.

He has a Ph.D. in Microbiology from Rockefeller University (RU) and a B.S. from Howard University. As an RU alum, he serves on both the RU Board of Trustees Educational Affairs Committee and the RU Ford Center Incubator selection committee. He is a member of the New York Academy of Sciences and a term member at the Council on Foreign Relations.

**About Armata Pharmaceuticals, Inc.**

Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa, S. aureus*, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

![](tm2612716d1_ex99-1img001.jpg)

**Forward Looking Statements**

This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

**Media Contacts:**

**At Armata:**

Pierre Kyme

ir@armatapharma.com

310-665-2928

**Investor Relations:**

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569